The GLP-1 class is the one segment where the same molecule exists in two markets at once: registered prescription pens at pharmacy counters, and research-grade vials from suppliers. The price gap between the two channels is the single most searched peptide-pricing question in the country, so here is the side-by-side. The pen column was read off the pharmacies' own product pages in August 2026, and every pen listed holds four weekly doses, so one pen is roughly one month.
| Molecule | Pharmacy Pen (Rx) | Research-Grade Vial | Notes |
|---|
| Semaglutide | ₱8,734 (Ozempic 1mg, Watsons) | ₱2,800–4,500 (5mg vial) | 0.25mg and 0.5mg pens ₱7,650; MedsGo lists 1mg at ₱7,850 on promo |
| Semaglutide 2.4mg tier | ₱12,650 (Wegovy 2.4mg, Watsons) | ₱2,800–4,500 (5mg vial) | Wegovy 0.25 to 1mg ₱9,900, 1.7mg ₱11,600 |
| Tirzepatide | ₱13,550 (Mounjaro KwikPen 5mg, Watsons) | ₱6,500–9,500 (30mg vial) | 2.5mg ₱11,650, 10mg ₱22,950, 12.5 and 15mg ₱29,900 |
| Retatrutide | Not available (Phase 3) | ₱5,500–8,500 (10mg vial) | No pharmacy route exists yet |
Two notes on reading this. The branded route is more expensive than the vial route, but not by the ten-to-one multiple that circulates online: against an Ozempic 0.5mg pen at ₱7,650, a ₱2,800 to 4,500 semaglutide vial is a gap of roughly two to three times, not an order of magnitude. And no mainstream Philippine pharmacy publishes a peso price for Rybelsus, the oral semaglutide tablet, or for the Ozempic 2mg pen, so this index carries neither; Zepbound has no Philippine registration I could identify.
The full channel-by-channel breakdowns live in the dedicated pricing filings: Ozempic Philippines price for the pen market, and weight loss peptides Philippines for the class ranked by trial results.